At Smartlens, we are transforming anterior segment disease management through breakthrough technologies that enable remote monitoring and care. Our flagship product, miLens, is the world's smallest wearable microfluidic device for diurnal IOP monitoring - the primary risk factor for glaucoma, the leading cause of irreversible blindness.
This non-invasive solution has earned strong market validation, with overwhelming adoption intent from eyecare practitioners across the U.S.
With a vision to transform anterior segment care, we're expanding beyond miLens to introduce our AI-powered platform for remote eye exams. Backed by extensive intellectual property, including more than 40 global patents and an exclusive Stanford license, we're building the first comprehensive solution that integrates monitoring, diagnosis, and treatment.
Our platform combines advanced microfluidic technology with AI-enhanced diagnostics to make specialist-level eye care more accessible and data-driven than ever.
Foundational research published on microfluidic pressure sensing technology
Selected as one of the 14 innovations that will change the world
Company established to commercialize breakthrough technology
Top finalist in Stanford Business School's One Start & Bases Challenge
Featured in major outlets including Fortune, BBC, and ABC News
Secured exclusive Stanford University license
Patent protection for miLens™ contact lens technology
Secured funding to advance development
Industry recognition for innovative technology
Novel miLens™ IOP monitoring technology
Received recognition from OCTANE
Non-invasive, personalized automated drug delivery
Demonstrated clinical efficacy
Secured funding for commercial advancement
Advanced data-driven insights for clinicians
Strengthened intellectual property position
Near commercial stage breakthrough technology for diurnal IOP monitoring
Comprehensive anterior segment disease management
miLens pilot study results presented at the AGS Annual Meeting: a novel contact lens system for measuring intraocular pressure, compared against Goldmann applanation and rebound tonometry.
American Glaucoma Society Annual Meeting
Our pilot data demonstrates the clinical efficacy of miLens in capturing diurnal IOP variations that traditional office-based measurements miss. This breakthrough validation represents a significant step toward transforming glaucoma management.
Learn More